Phase 1, Open-Label, Randomised Crossover Study Assessing the Tolerability and Acceptability of Long Acting Cabotegravir Intramuscular and Lenacapavir Subcutaneous Injections Over Time in Healthy Adults Without HIV
Latest Information Update: 20 May 2025
At a glance
- Drugs Cabotegravir (Primary) ; Lenacapavir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Sponsors ViiV Healthcare
Most Recent Events
- 20 May 2025 New trial record